Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols

Mette Toftager; Randi Sylvest; Lone Schmidt; Jeanette Bogstad; Kristine Løssl; Lisbeth Prætorius; Anne Zedeler; Thue Bryndorf; Anja Pinborg

doi:10.1016/j.fertnstert.2017.09.020

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols

Mette Toftager, Randi Sylvest, Lone Schmidt, Jeanette Bogstad, Kristine Løssl, Lisbeth Prætorius, Anne Zedeler, Thue Bryndorf, Anja Pinborg

11 Citationer (Scopus)

Abstract

OBJECTIVE: To compare self-reported quality of life, psychosocial well-being, and physical well-being during assisted reproductive technology (ART) treatment in 1,023 women allocated to either a short GnRH antagonist or long GnRH agonist protocol.

DESIGN: Secondary outcome of a prospective phase 4, open-label, randomized controlled trial. Four times during treatment a questionnaire on self-reported physical well-being was completed. Further, a questionnaire on self-reported quality of life and psychosocial well-being was completed at the day of hCG testing.

SETTING: Fertility clinics at university hospitals.

PATIENT(S): Women referred for their first ART treatment were randomized in a 1:1 ratio and started standardized ART protocols.

INTERVENTION(S): Gonadotropin-releasing hormone analogue; 528 women allocated to a short GnRH antagonist protocol and 495 women allocated to a long GnRH agonist protocol.

MAIN OUTCOME MEASURE(S): Self-reported quality of life, psychosocial well-being, and physical well-being based on questionnaires developed for women receiving ART treatment.

RESULT(S): Baseline characteristics were similar, and response rates were 79.4% and 74.3% in the GnRH antagonist and GnRH agonist groups, respectively. Self-reported quality of life during ART treatment was rated similar and slightly below normal in both groups. However, women in the GnRH antagonist group felt less emotional (adjusted odds ratio [AOR] 0.69), less limited in their everyday life (AOR 0.74), experienced less unexpected crying (AOR 0.71), and rated quality of sleep better (AOR 1.55). Further, women receiving GnRH agonist treatment felt worse physically.

CONCLUSION(S): Women in a short GnRH antagonist protocol rated psychosocial and physical well-being during first ART treatment better than did women in a long GnRH agonist protocol. However, the one item on self-reported general quality of life was rated similarly.

CLINICAL TRIAL REGISTRATION NUMBER: NCT00756028.

Originalsprog	Engelsk
Tidsskrift	Fertility and Sterility
Vol/bind	109
Udgave nummer	1
Sider (fra-til)	154-164
Antal sider	11
ISSN	0015-0282
DOI	https://doi.org/10.1016/j.fertnstert.2017.09.020
Status	Udgivet - jan. 2018

Adgang til dokumentet

10.1016/j.fertnstert.2017.09.020

Fingeraftryk

Dyk ned i forskningsemnerne om 'Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Toftager, M., Sylvest, R., Schmidt, L., Bogstad, J., Løssl, K., Prætorius, L., Zedeler, A., Bryndorf, T., & Pinborg, A. (2018). Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols. Fertility and Sterility, 109(1), 154-164. https://doi.org/10.1016/j.fertnstert.2017.09.020

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment : secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols. / Toftager, Mette; Sylvest, Randi; Schmidt, Lone et al.

I: Fertility and Sterility, Bind 109, Nr. 1, 01.2018, s. 154-164.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Toftager, M, Sylvest, R, Schmidt, L, Bogstad, J, Løssl, K, Prætorius, L, Zedeler, A, Bryndorf, T & Pinborg, A 2018, 'Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols', Fertility and Sterility, bind 109, nr. 1, s. 154-164. https://doi.org/10.1016/j.fertnstert.2017.09.020

Toftager M, Sylvest R, Schmidt L, Bogstad J, Løssl K, Prætorius L et al. Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols. Fertility and Sterility. 2018 jan.;109(1):154-164. doi: 10.1016/j.fertnstert.2017.09.020

Toftager, Mette ; Sylvest, Randi ; Schmidt, Lone et al. / Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment : secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols. I: Fertility and Sterility. 2018 ; Bind 109, Nr. 1. s. 154-164.

@article{3a871d36342b49e0a3d08549b72710a0,

title = "Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols",

abstract = "OBJECTIVE: To compare self-reported quality of life, psychosocial well-being, and physical well-being during assisted reproductive technology (ART) treatment in 1,023 women allocated to either a short GnRH antagonist or long GnRH agonist protocol.DESIGN: Secondary outcome of a prospective phase 4, open-label, randomized controlled trial. Four times during treatment a questionnaire on self-reported physical well-being was completed. Further, a questionnaire on self-reported quality of life and psychosocial well-being was completed at the day of hCG testing.SETTING: Fertility clinics at university hospitals.PATIENT(S): Women referred for their first ART treatment were randomized in a 1:1 ratio and started standardized ART protocols.INTERVENTION(S): Gonadotropin-releasing hormone analogue; 528 women allocated to a short GnRH antagonist protocol and 495 women allocated to a long GnRH agonist protocol.MAIN OUTCOME MEASURE(S): Self-reported quality of life, psychosocial well-being, and physical well-being based on questionnaires developed for women receiving ART treatment.RESULT(S): Baseline characteristics were similar, and response rates were 79.4% and 74.3% in the GnRH antagonist and GnRH agonist groups, respectively. Self-reported quality of life during ART treatment was rated similar and slightly below normal in both groups. However, women in the GnRH antagonist group felt less emotional (adjusted odds ratio [AOR] 0.69), less limited in their everyday life (AOR 0.74), experienced less unexpected crying (AOR 0.71), and rated quality of sleep better (AOR 1.55). Further, women receiving GnRH agonist treatment felt worse physically.CONCLUSION(S): Women in a short GnRH antagonist protocol rated psychosocial and physical well-being during first ART treatment better than did women in a long GnRH agonist protocol. However, the one item on self-reported general quality of life was rated similarly.CLINICAL TRIAL REGISTRATION NUMBER: NCT00756028.",

keywords = "Journal Article",

author = "Mette Toftager and Randi Sylvest and Lone Schmidt and Jeanette Bogstad and Kristine L{\o}ssl and Lisbeth Pr{\ae}torius and Anne Zedeler and Thue Bryndorf and Anja Pinborg",

year = "2018",

month = jan,

doi = "10.1016/j.fertnstert.2017.09.020",

language = "English",

volume = "109",

pages = "154--164",

journal = "Sexuality, Reproduction and Menopause",

issn = "1546-2501",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment

T2 - secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols

AU - Toftager, Mette

AU - Sylvest, Randi

AU - Schmidt, Lone

AU - Bogstad, Jeanette

AU - Løssl, Kristine

AU - Prætorius, Lisbeth

AU - Zedeler, Anne

AU - Bryndorf, Thue

AU - Pinborg, Anja

PY - 2018/1

Y1 - 2018/1

N2 - OBJECTIVE: To compare self-reported quality of life, psychosocial well-being, and physical well-being during assisted reproductive technology (ART) treatment in 1,023 women allocated to either a short GnRH antagonist or long GnRH agonist protocol.DESIGN: Secondary outcome of a prospective phase 4, open-label, randomized controlled trial. Four times during treatment a questionnaire on self-reported physical well-being was completed. Further, a questionnaire on self-reported quality of life and psychosocial well-being was completed at the day of hCG testing.SETTING: Fertility clinics at university hospitals.PATIENT(S): Women referred for their first ART treatment were randomized in a 1:1 ratio and started standardized ART protocols.INTERVENTION(S): Gonadotropin-releasing hormone analogue; 528 women allocated to a short GnRH antagonist protocol and 495 women allocated to a long GnRH agonist protocol.MAIN OUTCOME MEASURE(S): Self-reported quality of life, psychosocial well-being, and physical well-being based on questionnaires developed for women receiving ART treatment.RESULT(S): Baseline characteristics were similar, and response rates were 79.4% and 74.3% in the GnRH antagonist and GnRH agonist groups, respectively. Self-reported quality of life during ART treatment was rated similar and slightly below normal in both groups. However, women in the GnRH antagonist group felt less emotional (adjusted odds ratio [AOR] 0.69), less limited in their everyday life (AOR 0.74), experienced less unexpected crying (AOR 0.71), and rated quality of sleep better (AOR 1.55). Further, women receiving GnRH agonist treatment felt worse physically.CONCLUSION(S): Women in a short GnRH antagonist protocol rated psychosocial and physical well-being during first ART treatment better than did women in a long GnRH agonist protocol. However, the one item on self-reported general quality of life was rated similarly.CLINICAL TRIAL REGISTRATION NUMBER: NCT00756028.

AB - OBJECTIVE: To compare self-reported quality of life, psychosocial well-being, and physical well-being during assisted reproductive technology (ART) treatment in 1,023 women allocated to either a short GnRH antagonist or long GnRH agonist protocol.DESIGN: Secondary outcome of a prospective phase 4, open-label, randomized controlled trial. Four times during treatment a questionnaire on self-reported physical well-being was completed. Further, a questionnaire on self-reported quality of life and psychosocial well-being was completed at the day of hCG testing.SETTING: Fertility clinics at university hospitals.PATIENT(S): Women referred for their first ART treatment were randomized in a 1:1 ratio and started standardized ART protocols.INTERVENTION(S): Gonadotropin-releasing hormone analogue; 528 women allocated to a short GnRH antagonist protocol and 495 women allocated to a long GnRH agonist protocol.MAIN OUTCOME MEASURE(S): Self-reported quality of life, psychosocial well-being, and physical well-being based on questionnaires developed for women receiving ART treatment.RESULT(S): Baseline characteristics were similar, and response rates were 79.4% and 74.3% in the GnRH antagonist and GnRH agonist groups, respectively. Self-reported quality of life during ART treatment was rated similar and slightly below normal in both groups. However, women in the GnRH antagonist group felt less emotional (adjusted odds ratio [AOR] 0.69), less limited in their everyday life (AOR 0.74), experienced less unexpected crying (AOR 0.71), and rated quality of sleep better (AOR 1.55). Further, women receiving GnRH agonist treatment felt worse physically.CONCLUSION(S): Women in a short GnRH antagonist protocol rated psychosocial and physical well-being during first ART treatment better than did women in a long GnRH agonist protocol. However, the one item on self-reported general quality of life was rated similarly.CLINICAL TRIAL REGISTRATION NUMBER: NCT00756028.

KW - Journal Article

U2 - 10.1016/j.fertnstert.2017.09.020

DO - 10.1016/j.fertnstert.2017.09.020

M3 - Journal article

C2 - 29175067

SN - 1546-2501

VL - 109

SP - 154

EP - 164

JO - Sexuality, Reproduction and Menopause

JF - Sexuality, Reproduction and Menopause

IS - 1

ER -